Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
2025.11.07
Marketing Authorization Applications for Boan Biotech’s Two Denosumab Injections Accepted in the UK
2025.10.31
BA1104 Phase III Trial in China Completes Patient Enrollment
2025.10.20
Boan Biotech Presents Early Findings about BA1301 at ESMO 2025
28
2025-08
Boan Biotech Announces 2025 Half-Year Results
08
2025-08
Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing
15
2025-07
Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert
17
2025-06
Boan Receives FDA IND Clearance for Its CD228-Directed ADC
12
2025-06
Boan Grants Shaphar Right to Commercialize BA5101 in China
30
2025-04
Boan Biotech Presents Early Research Findings about Its Innovative Anti-CD25 Antibody (BA1106) at AACR Annual Meeting 2025
22
2025-04
Phase 3 Trial Results of Boan Biotech’s Dulagutide Injection Published in Journal of Diabetes
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
